MNPR — Monopar Therapeutics
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1645469 ·
Last close
$108.35
Market Cap
$725.84M
52W High
$116.68
52W Low
$50.60
ADV30
255,509
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -5,225,253 | -3,893,050 | 137,983,725 | 52,544,263 | 2,589,313 |
| Dec 2025 | 0 | — | -6,155,228 | -5,200,795 | 140,717,709 | 61,833,552 | 2,890,156 |
| Sep 2025 | 0 | — | -4,093,075 | -3,437,601 | 144,197,278 | 127,677,360 | 2,639,430 |
| Jun 2025 | 0 | — | -3,234,295 | -2,453,526 | 53,865,873 | 39,501,936 | 1,663,979 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-10,011,881
Investing CF
$-68,710,838
Financing CF
$91,489,881
CapEx
—
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$-1.67
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-93,402,580
Inventory
—
Receivables
—
ST Investments
$84,948,677
EBIT TTM
$-18,707,851
Pretax Income TTM
$-14,984,972
Interest Exp TTM
—
Analysts
13
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -16,704,415 | -13,716,894 | 140,717,709 | 2,890,156 | — | -12,201,291 |
| Dec 2024 | 0 | -16,161,721 | -15,586,419 | 60,291,071 | 5,254,300 | — | -6,404,139 |
| Dec 2023 | 0 | -8,831,235 | -8,402,196 | 7,345,159 | 1,757,393 | — | -7,858,293 |
| Dec 2022 | 0 | -10,536,877 | -10,515,638 | 13,226,954 | 3,137,302 | — | -7,228,559 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-3.13
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ACRS | Aclaris Therapeutics, Inc. | $726.25M | $5.20 | — |
| DRUG | BRIGHT MINDS BIOSCIENCES INC. | $718.83M | $73.26 | — |
| PHAR | Pharming Group N.V. | $713.44M | $10.08 | — |
| XOMA | XOMA Royalty Corp | $710.16M | $40.17 | — |
| PHAT | Phathom Pharmaceuticals, Inc. | $707.88M | $8.75 | — |
News headlines (Yahoo Finance, 1h cache)
Monopar Initiates Rolling NDA Submission for ALXN1840 in Wilson Disease
2026-07-22 12:00 · Yahoo
Monopar Advances Launch Readiness with Addition of Veteran Commercial Executive Nicole Sweeny to Board of Directors and Expansion of Commercial Leadership Team
2026-07-20 12:00 · Yahoo
Monopar Therapeutics Receives FDA Rare Pediatric Disease Designation for ALXN1840 for the Treatment of Wilson Disease
2026-06-30 12:00 · Yahoo
Monopar Presents New Analyses of Phase 3 FoCus Data at EAN 2026 Showing Greater Neurologic and Global Clinical Benefit with ALXN1840 Versus Standard of Care in Wilson Disease
2026-06-26 20:05 · Yahoo
Wall Street Analysts Believe Monopar Therapeutics (MNPR) Could Rally 88.92%: Here's is How to Trade
2026-06-15 13:55 · Yahoo
Monopar Presents Phase 2 ALXN1840 Data Demonstrating Liver Disease Stabilization and Neurologic Improvement in Treatment-Experienced Wilson Disease Patients at EASL 2026
2026-06-01 11:00 · Yahoo
Monopar Announces Publication of Phase 2 Study Demonstrating ALXN1840 Significantly Improves Copper Balance in Patients with Wilson Disease
2026-05-19 21:33 · Yahoo
Monopar Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
2026-05-14 18:00 · Yahoo
Monopar Therapeutics (NASDAQ:MNPR) Is In A Good Position To Deliver On Growth Plans
2026-05-03 13:26 · Yahoo
Monopar Presents Phase 3 Data Showing Greater Neurologic Benefit with ALXN1840 vs SoC in Wilson Disease Patients with Neurologic Symptoms at AAN 2026
2026-04-19 23:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.